Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohan V Bala

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Health economic analysis of new interventions: are we asking the right questions?Mohan V Bala
Pharmacogenomics|December 23, 2006
Overview of the pharmacoeconomics of pharmacogeneticsThierry Dervieux, Mohan V Bala
Pharmacoeconomics|May 18, 2005
On pharmacogenomics and cost-effectiveness analysis at the individual levelMohan V Bala, Gary A Zarkin
Pharmacoeconomics|April 12, 2006
Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic conceptsMohan V Bala, Josephine A Mauskopf
The American Journal of Managed Care|March 28, 2002
Application of cost-effectiveness analysis to multiple products: a practical guideMohan V Bala, Gary A Zarkin
Pharmacoeconomics|June 26, 2004
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?Mohan V Bala, Gary A Zarkin
Health Economics|August 19, 2007
Presenting results of probabilistic sensitivity analysis: the incremental benefit curveMohan V Bala, Gary A Zarkin, Josephine Mauskopf
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Conditions for the near equivalence of cost-effectiveness and cost-benefit analysesMohan V Bala, Gary A Zarkin, Josephine A Mauskopf
Journal of Medical Economics|May 20, 2009
A case-control study of anaemia in patients with rheumatoid arthritis treated with disease-modifying antirheumatic drugs in an adult population in the US: prevalence and impact on healthcare utilisationChenglong Han, Ning Zhao, Mahboob U Rahman, et al.
The Journal of Rheumatology|September 19, 2006
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisChenglong Han, Don W Robinson, Monica V Hackett, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Health economic analysis of new interventions: are we asking the right questions?Mohan V Bala
Pharmacogenomics|December 23, 2006
Overview of the pharmacoeconomics of pharmacogeneticsThierry Dervieux, Mohan V Bala
Pharmacoeconomics|May 18, 2005
On pharmacogenomics and cost-effectiveness analysis at the individual levelMohan V Bala, Gary A Zarkin
Pharmacoeconomics|April 12, 2006
Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic conceptsMohan V Bala, Josephine A Mauskopf
The American Journal of Managed Care|March 28, 2002
Application of cost-effectiveness analysis to multiple products: a practical guideMohan V Bala, Gary A Zarkin
Pharmacoeconomics|June 26, 2004
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?Mohan V Bala, Gary A Zarkin
Health Economics|August 19, 2007
Presenting results of probabilistic sensitivity analysis: the incremental benefit curveMohan V Bala, Gary A Zarkin, Josephine Mauskopf
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Conditions for the near equivalence of cost-effectiveness and cost-benefit analysesMohan V Bala, Gary A Zarkin, Josephine A Mauskopf
Journal of Medical Economics|May 20, 2009
A case-control study of anaemia in patients with rheumatoid arthritis treated with disease-modifying antirheumatic drugs in an adult population in the US: prevalence and impact on healthcare utilisationChenglong Han, Ning Zhao, Mahboob U Rahman, et al.
The Journal of Rheumatology|September 19, 2006
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisChenglong Han, Don W Robinson, Monica V Hackett, et al.
Pageof 1